Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Nuvilex, Inc. (NVLX)

NVLX RSS Feed
Add NVLX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Alydyr, Pennystockplayer, thnikkamax, Peacefulwendy, TheBestInvest
Search This Board:
Last Post: 8/20/2014 5:22:43 PM - Followers: 473 - Board type: Free - Posts Today: 45

                                                                        


Nuvilex      

NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)

                                            

Nuvilex Company Address
   Nuvilex, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851
   email: info@nuvilex.com


Shares Outstanding:
593,411,348 a/o Dec 13, 2013

Authorized Shares:
N/A

Float:
N/A
For more updated information please visit: 
http://www.otcmarkets.com/stock/NVLX/company-info



Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations
Marlin Molinaro
Marmel Communications, LLC
Phone: (702) 434-8692
email: mmolinarofc@aol.com


                                               

All News Releases: 
http://www.nuvilex.com/latest-news


Nuvilex is a biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, called Cell-in-a-Box(TM). This unique technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. The Company's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids. To do so, it will examine ways to exploit the benefits of Cell-in-a-Box(TM) technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide.

Nuvilex has acquired worldwide exclusive rights to the cellulose-based live cell-encapsulation technology, also known as Cell-in-a-Box™, and described above, from SG Austria Pte. Ltd. for the development of treatments for any and all types of cancer. The rights to use the cancer drug-activating cells that will be part of Nuvilex’s treatment for advanced pancreatic cancer (see Pancreatic Cancer section of this website) were also acquired. The acquisition of rights to use the Cell-in-a-Box™ technology for the development of treatments for insulin-dependent diabetes has recently been completed.

Austria Nova Demonstration Video


 

SMMG Radio Interview with COO Dr. Crabtree ~ 2013





Shareholder Update with CEO & COO via SMMG Interview ~ July 2014






The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool.

 

Medical Marijuana Sciences

 
                                                                                                                                   

                                                       



 


Management Team:
 

Kenneth L. Waggoner, Chief Executive Officer and President:

Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.

Dr. Robert F. Ryan, Chief Scientific Officer:

 

Dr. Robert F. Ryan was named Chief Scientific Officer. Dr. Ryan has broad scientific experience in biochemistry, cell and molecular biology, human genetics, novel therapies, and basic and clinical cancer research, having received his Masters in Biochemistry, Cell and Molecular Biology at The Medical College of Georgia, studying sickle cell anemia. He received his Ph.D. in Molecular Genetics at Thomas Jefferson University characterizing DNA and RNA binding properties of zinc finger proteins. Through his extensive training, his experiences extend across the fields of aging, hemoglobinopathies, gene expression, human diseases, DNA, RNA, proteins and their interactions, stem cell research and applications, oncology, clinical protocols and therapies.

Professionally, Dr. Ryan has become a pioneer in the field of emerging biotechnology, specializing in assisting small companies with insight and bringing products to market through the rigorous FDA approval process. Since 2002, Dr. Ryan served as the Chief Executive Officer of RFR Consulting where he focused on helping businesses in the biotech industry through providing information, grant writing, business management, scientific guidance, FDA regulatory advice, advising investors, and investment acquisition opportunities. With 25 years experience including excellent training at the Wistar Institute, NIH, and NCI, he has participated in basic and clinical investigations and has published and edited research articles in several peer-reviewed journals.

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

 

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Patricia Gruden – Chief Financial Officer and Chairman of the Board:

 

Patricia Gruden is the Chief Financial Officer of the Company and Chairman of the Board.  Ms. Gruden has made a substantial impact on the Company since its inception.  In 1995, Ms. Gruden became cofounder of the company that later became Nuvilex, Inc.  The original company was initiated to develop a software program through accurately tracking produce from the field to the table, including the challenges of shipping, temperature variation and maintenance and everything else concerning the distribution of produce worldwide.  In addition, the Company developed an ozone cleaning system to kill bacteria on produce without leaving harmful residue on the product and without harming the environment. 

Over the years Ms. Gruden has carried out almost every job in the Company, including developer, shipper, President, CEO, Chairman of the Board, CFO and many others.  As a result, she has been intricately aware of all aspects of the Company and its products.  After a brief semi-retirement in 2009-10, Ms. Gruden returned to make arrangements for necessary funding and to assist the Company in changing from a nutraceutical company to a biotechnology company.  Her training has not only included real world experiences of running more than one company, Ms. Gruden embraces every business opportunity with excitement, clarity and focus.  Ms. Gruden has a long history of owning her own businesses and doing so successfully. Additionally, a strong community presence allowed her to act as President of the local Chamber of Commerce and Arizona Small Business Association.  She has also been active in Habitat for Humanity, shelters for abused women and children and the Ronald McDonald House.

 

Stock Chart http://www.otcmarkets.com/stock/NVLX/chart
Company Info http://www.otcmarkets.com/stock/NVLX/company-info
Recent News http://www.otcmarkets.com/stock/NVLX/news
Financials http://www.otcmarkets.com/stock/NVLX/financials
Filings and Disclosure http://www.otcmarkets.com/stock/NVLX/filings
Short Sales http://www.otcmarkets.com/stock/NVLX/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/NVLX/insider-transactions
Research Reports http://www.otcmarkets.com/stock/NVLX/research
Summary http://finance.yahoo.com/q?s=NVLX
Historical Prices http://finance.yahoo.com/q/hp?s=NVLX+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=NVLX
Basic Chart http://finance.yahoo.com/q/bc?s=NVLX+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=NVLX+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=NVLX+Headlines
Press Releases http://finance.yahoo.com/q/p?s=NVLX+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=NVLX+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=NVLX+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=NVLX+Industry
Major Holders http://finance.yahoo.com/q/mh?s=NVLX+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=NVLX+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=NVLX+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=NVLX
Balance Sheet http://finance.yahoo.com/q/bs?s=NVLX
Cash Flow http://finance.yahoo.com/q/cf?s=NVLX+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/NVLX
Market Watch http://www.marketwatch.com/investing/stock/NVLX
Bloomberg http://www.bloomberg.com/quote/NVLX:US
Morningstar http://quotes.morningstar.com/stock/s?t=NVLX
Bussinessweek http://investing.businessweek.com/research/st...icker=NVLX
Barchart http://www.barchart.com/quotes/stocks/NVLX
OTC Short Report http://otcshortreport.com/index.php?index=NVLX
Investopedia http://www.investopedia.com/markets/stocks/NVLX/?wa=0


                                 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NVLX
Current Price
Volume:
Bid Ask Day's Range
Wiki
NVLX News: Annual Report (10-k) 08/04/2014 08:12:35 AM
NVLX News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 07/30/2014 03:24:07 PM
NVLX News: Nuvilex and Austrianova Announce Results of Clinical Trial in Dogs with Mammary Tumors Treated With Cell-in-a-Box(R) Plus Cyc... 07/17/2014 09:00:00 AM
NVLX News: Nuvilex Provides Shareholder Update on Milestone Accomplishments 07/14/2014 09:00:00 AM
NVLX News: Nuvilex Executives Attend 2014 BIO International Convention 07/01/2014 09:00:00 AM
PostSubject
#25384  Sticky Note SHAREHOLDER DILUTION at NVLX Alydyr 08/20/14 04:30:41 PM
#24661  Sticky Note This website hosts an amazing collection of Nuvilex's Marleebone 08/01/14 01:37:46 PM
#24584  Sticky Note What is Cell-in-the-Box? PetePham 07/28/14 04:14:36 PM
#20481  Sticky Note Normally I might be inclined to agree with Going Coastal 05/02/14 03:16:58 PM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#25395   Such a very important point you are making Peacefulwendy 08/20/14 05:22:43 PM
#25394   :) I have to agree that $$$ Peacefulwendy 08/20/14 05:17:45 PM
#25393   Agreed with you bulldurham... I am ready to PetePham 08/20/14 05:05:11 PM
#25392   Another thing that they are always missing and bulldurham 08/20/14 05:05:05 PM
#25391   If investing is like baseball I wood b HighHoeSilverado 08/20/14 04:59:07 PM
#25390   Same here Wendy...I am be able to get PetePham 08/20/14 04:54:12 PM
#25389   When TD2 reports Nuvilex's results with Cell-in-a-Box(R), pre-clinical Peacefulwendy 08/20/14 04:52:47 PM
#25388   Real longs in Nuvilex are not worried about bulldurham 08/20/14 04:48:31 PM
#25387   "Investing is like baseball. If you want to Peacefulwendy 08/20/14 04:44:02 PM
#25386   with today news which I have to admit thenewmixer 08/20/14 04:36:44 PM
#25385   NUVILEX has MASSIVE POTENTIAL that cannot be ignored... bulldurham 08/20/14 04:30:44 PM
#25384   SHAREHOLDER DILUTION at NVLX Alydyr 08/20/14 04:30:41 PM
#25383   Long ago I learnt myself that " It HighHoeSilverado 08/20/14 04:16:51 PM
#25382   Nuvilex has the very credible, experienced with FDA Peacefulwendy 08/20/14 04:13:56 PM
#25381   Nuvilex Has Massive Credibility Issues and They Can’t Hotelier51 08/20/14 04:05:57 PM
#25380   Nuvilex Begins Preclinical Studies With Translational Drug Development ostowari 08/20/14 03:35:45 PM
#25378  Restored "Long ago, Ben Graham taught me that 'Price Peacefulwendy 08/20/14 03:18:52 PM
#25375   Diff is I have actually made $400-$500 so HighHoeSilverado 08/20/14 02:48:17 PM
#25374   I bought in @ .24s too and hoping Peacefulwendy 08/20/14 02:45:19 PM
#25372   Nuvilex's CEO and President added, "We are confident PetePham 08/20/14 02:27:38 PM
#25370   I don't even want one. Let's roll solo ducks2312 08/20/14 12:26:01 PM
#25369   It is looking good here with new result PetePham 08/20/14 12:23:33 PM
#25368   LOOKING GREAT HERE AT NUVILEX STUDY UNDERWAY...just what bulldurham 08/20/14 12:16:23 PM
#25367   Not looking good here at NVLX. Alydyr 08/20/14 12:12:24 PM
#25366   I'm back in with a couple .24s. Hoping HighHoeSilverado 08/20/14 12:00:28 PM
#25365   C'mon .22s Chevy needs a new pair of shoes. HighHoeSilverado 08/20/14 10:50:30 AM
#25364   The support is futile. This pr will drag HighHoeSilverado 08/20/14 10:23:00 AM
#25363   Yikes....This Already Had Mice Trials...in 1998. Hotelier51 08/20/14 10:19:22 AM
#25360   In the studies being conducted by TD2, mice PetePham 08/20/14 09:38:22 AM
#25359   $NVLX Major News PetePham 08/20/14 09:34:17 AM
#25358   A second group of mice will be treated bulldurham 08/20/14 09:29:42 AM
#25357   Nevermind Bull, you were right. I just jzsplace 08/20/14 09:27:22 AM
#25355   did you see a a second group of bulldurham 08/20/14 09:19:33 AM
#25354   Yes and we are ready for Fast Track PetePham 08/20/14 09:16:21 AM
#25353   Do u think this pr will drag the HighHoeSilverado 08/20/14 09:14:23 AM
#25352   It's Begun! Forward We March...Nuvilex Versus Cancer...Go Nuvilex... Setay 08/20/14 09:12:32 AM
#25351   Nuvilex Begins Preclinical Studies With Translational Drug Development bulldurham 08/20/14 09:10:33 AM
#25349   Pete, I am adding to my position as Peacefulwendy 08/19/14 09:20:48 PM
#25348   Agreed. Friday PR will be release and the PetePham 08/19/14 08:34:40 PM
#25346   Dr Von Hoff is probably injecting mice as Emmmci 08/19/14 07:16:44 PM
#25345   This quote has appeared on this message board Marleebone 08/19/14 07:08:55 PM
#25344   wow that sounds great what year was that? thenewmixer 08/19/14 05:36:33 PM
#25343   In total, 27 patients with advanced, inoperable pancreatic PetePham 08/19/14 05:33:54 PM
#25342   Mr. Waggoner concluded, "With the publication of this PetePham 08/19/14 05:32:46 PM
#25341   Professor Dr. Walter H. Gunzburg, Austrianova's Chairman of PetePham 08/19/14 05:29:51 PM
#25340   Ne1 else see the .22s in the near HighHoeSilverado 08/19/14 05:27:54 PM
#25339   Nuvilex Announces Publication of Combined Results of the PetePham 08/19/14 05:26:52 PM
#25338   Why doesn't KW have a conference call thenewmixer 08/19/14 04:56:00 PM
#25337   Too little money. Too many red flags and Hotelier51 08/19/14 04:18:01 PM
#25336   Thanks for those low PPS today. I am PetePham 08/19/14 04:03:41 PM
PostSubject